Prolonged suppression of monocytic human leukocyte antigen-DR expression correlates with mortality in pediatric septic patients in a pediatric tertiary Intensive Care Unit

Journal of Critical Care

Volumn 33, Issue , 2016, Pages 84-89

  Manzoli, Talita Freitas ^a   Troster, Eduardo Juan ^a   Ferranti, Juliana Ferreira ^a   Sales, Maria Mirtes ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

HLA DR; Immunoparalysis; Monocytic HLA DR; Pediatric intensive care; Sepsis; Septic shock

Indexed keywords

HLA ANTIGEN; HLA DR ANTIGEN; VASOACTIVE AGENT;

ANTIGEN EXPRESSION; ARTICLE; ARTIFICIAL VENTILATION; BRAZIL; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HUMAN; INTENSIVE CARE UNIT; MALE; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; TERTIARY HEALTH CARE; ADOLESCENT; BLOOD; CASE CONTROL STUDY; CHILD HEALTH CARE; IMMUNOLOGY; INFANT; INTENSIVE CARE; MONOCYTE; PEDIATRIC INTENSIVE CARE UNIT; PRESCHOOL CHILD;

ADOLESCENT; BRAZIL; CASE-CONTROL STUDIES; CHILD; CHILD HEALTH SERVICES; CHILD, PRESCHOOL; COHORT STUDIES; CRITICAL CARE; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; INFANT; INTENSIVE CARE UNITS, PEDIATRIC; MALE; MONOCYTES; PROSPECTIVE STUDIES; SHOCK, SEPTIC;

EID: 84959207072     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2016.01.027     Document Type: Article

References (41)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: ACCP/SCCM Consensus Conference: Definitions for sepse and organ failure and guidelines for the use of innovative therapies in sepse. Crit Care Med 1992, 20:864-874.
2. Goldstein Brahm, Giroir Brett, Randolph Adrienne Members of the International Consensus Conference on Pediatric Sepsis - International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005, 6(1):2-8.
3. Carcillo JA. Critical Illness Stress-induced Immune Suppression - Yearbook of Intensive Care and Emergency Medicine, 2007, Part 4, 217-228.
4. Bone R.C., Balk R.A., Fein A.M., Perl T.M., Wenzel R.P., Reines H.D., et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 1995, 23(6):994-1006.
5. Opal S.M., Fisher C.J., Dhainaut J.F., Vincent J.L., Brase R., Lowry S.F., et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997, 25(7):1115-1124.
6. Cohen J., Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996, 24(9):1431-1440.
7. Polk H.C., Welhausen S.R., Regan M. A systematic study of host defense processes in badly injured patients. Ann Surg 1986, 204(3):282-297.
8. Frazier W.Joshua, Hall Mark W. Immunoparalysis and Adverse Outcomes from Critical Illness. Pediatr Clin North Am 2008, 55(3):647-668.
9. Volk H.D., Thieme M., Heym S., Docke W.D., Ruppe U., Tausch W., et al. Alterations in function and phenotype of monocytes from patients with septic disease- predictive value and new therapeutic strategies. Behring Inst Mitt 1991, 208-215.
10. Volk H.D., Reinke P., Krausch D., Zuckermann H., Asadullah K., Müller J.M., et al. Monocyte deactivation rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996, 22:S474-S481.
11. Rivers Emanuel, Nguyen Bryant, Havstad Suzanne, Ressler Julie, Muzzin Alexandria, Knoblich Bernhard, Peterson Edward, Tomlanovich Michael Early Goal Directed Therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377.
12. Stoll B.J., Holman R.C., Schuchat A. Decline in sepsis-associated neonatal and infant deaths in the United States, 1979 through 1994. Pediatrics 1998, 102(2):e18.
13. Watson R.S., Carcillo J.A., Linde-Zwirble W.T., Clermont G., Lidicker J., Angus D.C. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003, 167:695-701.
14. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29(7):1303-1310.
15. Meisel C., Schefold J.C., Pschowski R., Baumann T., Hetzger K., Gregor J., et al. Granulocyte-macrophage colony- stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009, 180(7):640-648. [Epub 2009 Jul 9].
16. Schefold J.C., Zeden J.P., Pschowski R., Hammoud B., Fotopoulou C., Hasper D., et al. Scand - Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock. J Infect Dis 2010, 42(3):164-171.
17. Döcke Wolf-Dietrich, Höflich Conny, Davis Kenneth A., Röttgers Karsten, Meisel Christian, Kiefer Paul, et al. Monitoring Temporary Immunodepression by Flow Cytometric Measurement of Monocytic HLA-DR Expression: A Multicenter Standardized Study. Clin Chem 2005, 51(12):2341-2347.
18. Trimmel H., Luschin U., Köhrer K., Anzur C., Vevera D., Spittler A. Clinical outcome of critically ill patients cannot be defined by cutoff values of monocyte human leukocyte antigen-DR expression. Shock 2012, 37(2):140-144.
19. Wisgrill L., Spittler A., Hartmann J., Lamm C., Preiing F., Dragosits K., et al. SEP-1: Time and temperature dependent changes of LPS induced TNF-α secretion, monocyte HLA-DR expression and IL-6 levels in different anticoagulated whole blood samples. Shock September 2015, (44 Suppl 2):14. 10.1097/01.shk.0000472045.00008.05.
20. Slater A., Shann F., Pearson G. Paediatric Index of Mortality (PIM) Study Group. PIM2: a revised version of the Paediatric Index of Mortality. Intensive Care Med 2002, 28:105-107.
21. Pollack M.M., Ruttimann U.E., Getson P.R. The Pediatric Risk of Mortality (PRISM) score. Crit Care Med 1996, 24:743-752.
22. Poehlmann H., Schefold J.C., Zuckermann-Becker H., Volk H.D., Meisel C. Phenotype changes and impaired function of dendritic cell subsets in patients with sepsis: a prospective observational analysis. Crit Care 2009, 13(4):R119. Jul 15.
23. Perry S.E., Mostafa S.M., Wenstone R., Shenkin A., McLaughlin P.J. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis?. Intensive Care Med 2003, 29(8):1245-1252. [Epub 2003 May 28].
24. Muller Kobold A.C., Tulleken J.E., Zijlstra J.G., Sluiter W., Hermans J., Kallenberg C.G., et al. Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med 2000, 26(7):883-892.
25. Oberhoffer M., Vogelsang H., Russwurm S., Hartung T., Reinhart K. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med 1999, 37(3):363-368. [Erratum in: Clin Chem Lab Med 1999 Jun;37(6):697].
26. Hynninen M., Pettilä V., Takkunen O., Orko R., Jansson S.E., Kuusela P., et al. Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis.- Shock 2003, 20(1):1-4.
27. Monneret G., Lepape A., Voirin N., Bohé J., Venet F., Debard A.L., et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006, 32(8):1175-1183. [Epub 2006 Jun 2].
28. Monneret G., Elmenkouri N., Bohe J., Debard A.L., Gutowski M.C., Bienvenu J., et al. Analytical requirements for measuring monocytic human lymphocyte antigen DR by flow cytometry: application to the monitoring of patients with septic shock. Clin Chem 2002, 48(9):1589-1592.
29. Hall M.W., Knatz N.L., Vetterly C, Tomarello S., Wewers MD, Volk H.D., et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med 2011, 37:525-532.
30. Ploder M., Pelinka L., Schmuckenschlager C., Wessner B., Ankersmit H.J., Fuerst W., et al. Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock 2006, 25(2):129-134.
31. Genel F., Atlihan F., Ozsu E., Ozbek E. Monocyte HLA-DR expression as predictor of poor outcome in neonates with late onset neonatal sepsis. J Infect 2010, 60(3):224-228. [Epub 2009 Dec 16].
32. Carcillo J.A. Critical Illness Stress-induced Immune Suppression. Year book of Intensive Care and Emergency Medicine 2007, 217-228. [Part 4].
33. Monneret G., Debard A.L., Venet F., Bohe J., Hequet O., Bienvenu J., et al. Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med 2003, 31(7):2068-2071.
34. Kocher A.A., Dockal M., Weigel G., Griessmacher A., Grimm M., Ehrlich M., et al. Immune Monitoring in Cardiac Transplant Recipientes. Transplant Proc 1997, 29:2895-2898.
35. Payen D., Faivre V., Lukaszewicz A.C., Villa F., Goldberg P. Expression of monocyte human leukocyte antigen-DR in relation with sepsis severity and plasma mediators. Minerva Anestesiol 2009, 75(9):484-493.
36. Tschaikowsky K., Hedwig-Geissing M., Schiele A., Bremer F., Schywalsky M., Schüttler J. Coincidence of pro- and anti-inflammatory responses in the early phase of severe sepsis: Longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med 2002, 30(5):1015-1023.
37. Lukaszewicz A.C., Grienay M., Resche-Rigon M., Pirracchio R., Faivre V., Boval B., et al. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit Care Med 2009, 37(10):2746-2752.
38. Kirsch M., Boval B., Damy T., Ghendouz S., Vermes E., Loisance D., et al. Importance of monocyte deactivation in determining early outcome after ventricular assist device implantation. Int J Artif Organs 2012, 35(3):169-176. 10.5301/ijao.5000053.
39. Asadullah K., Woiciechowsky C., Döcke W.-D., Egerer K., Kox W.J., Vogel S., et al. Very Low monocytic HLA-DR expression. Indicates high risk of infection - Immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur J Emerg Med 1995, 2:179-245.
40. Allen M.L., Peters M.J., Goldman A., Elliott M., James I., Callard R., et al. Early postoperative monocyte deactivation predicts systemic inflammation and prolonged stay in pediatric cardiac intensive care. Crit Care Med 2002, 30(5):1140-1145.
41. Hoffman J.A., Weinberg K.I., Azen C.G., Horn M.V., Dukes L., Starnes V.A., et al. Human leukocyte antigen-DR expression on peripheral blood monocytes and the risk of pneumonia in pediatric lung transplant recipients. Transpl Infect Dis 2004, 6(4):147-155.